Stathopoulos G P, Koutantos J, Lazaki H, Rigatos S K, Stathopoulos J, Deliconstantinos G
First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece.
Anticancer Res. 2007 May-Jun;27(3B):1653-6.
Capecitabine (Xeloda) is a fluoropyrimidine which is transformed to 5-fluorouracil (5-FU) at the tumor site. The aim of the present study was to estimate the efficacy of this agent in pretreated patients with advanced breast and colorectal cancer, and to determine the response rate and adverse reactions.
Forty-two patients (median age 65 years, range 27-80 years), 24 with breast cancer, 17 with colorectal cancer and one with a pancreatic islet tumor were included. Capecitabine was administered at a dose of 1200 mg/m2 twice daily for two weeks every 21 days. No other agent or supportive treatment was planned.
A partial response was observed in 29.16% of the patients with breast cancer and in 11.76% of the patients with colorectal cancer. Stable disease was observed in 58.33% and 70.59% of the breast cancer and colorectal patients, respectively. Adverse reactions were very mild with respect to myelotoxicity and GI tract toxicity. Grade 3 hand-foot syndrome was observed in three patients (7.14%). Hypertriglyceridemia, an unusual side-effect, was observed in 5/12 patients who were tested for serum cholesterol triglycerides.
Capecitabine is a well tolerated treatment with low toxicity, rendering a partial response in 29.16% and 11.76% of patients with breast and colorectal cancer, respectively.
卡培他滨（希罗达）是一种氟嘧啶，在肿瘤部位转化为5-氟尿嘧啶（5-FU）。本研究的目的是评估该药物在晚期乳腺癌和结直肠癌预处理患者中的疗效，并确定缓解率和不良反应。
纳入42例患者（中位年龄65岁，范围27 - 80岁），其中24例为乳腺癌患者，17例为结直肠癌患者，1例为胰岛细胞瘤患者。卡培他滨以1200 mg/m²的剂量每日两次给药，每21天持续两周。未计划使用其他药物或支持性治疗。
乳腺癌患者中有29.16%观察到部分缓解，结直肠癌患者中有11.76%观察到部分缓解。乳腺癌和结直肠癌患者中分别有58.33%和70.59%观察到病情稳定。关于骨髓毒性和胃肠道毒性，不良反应非常轻微。3例患者（7.14%）观察到3级手足综合征。在12例检测血清胆固醇甘油三酯的患者中，5例出现高甘油三酯血症，这是一种不常见的副作用。
卡培他滨是一种耐受性良好、毒性低的治疗方法，分别使29.16%的乳腺癌患者和11.76%的结直肠癌患者出现部分缓解。
Zotero 插件